Kati Copley-Merriman, MS, MBA Vice President of Regulatory and Health Outcomes Strategy and Market Access has been elected to serve as a director on the board of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The position is a 2 year appointment. She will take office in May at the ISPOR 15th Annual International Meeting in Atlanta, Georgia.
Kati has served as co-chair of the ISPOR short course committee and has been involved in ISPOR every year since the first meeting. Kati was also chair of the PhRMAh Health Outcomes Technical committee and served on the committee for eight years.
Ms. Copley-Merriman has more than 25 years of industry experience, including leadership roles in Global Outcomes Research at several international pharmaceutical companies. She has experience in all aspects of Outcomes Research (OR), including clinical trial design with PRO endpoints, economic evaluations, OR strategic plans, and regulatory strategy. Ms. Copley-Merriman has experience in many therapeutic areas, including oncology, pain and inflammation, dermatology, respiratory, urology, and CNS.
“I am thrilled to serve in this important role, said Ms. Copley-Merriman. “ISPOR is uniquely suited to bring together all the stakeholders who evaluate the value of new technologies and to match the interests of policy makers with the researchers who provide the value evidence. I look forward to being a collaborative voice in these efforts.”
ISPOR is an international, educational and scientific organization that fosters excellence in the core disciplines of pharmacoeconomics (health economics) and outcomes research and the use of this research information in health care decisions at all levels.
See http://www.ispor.org for more information.